Agios Pharmaceuticals, Inc. (AGIO) Stock Score, Valuation & Financial Research
Agios Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for AGIO
Agios Pharmaceuticals, Inc. currently has a Wall Street Score of 32/100. The stored market price is $33.6. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Agios Pharmaceuticals, Inc. does
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $33.6
- Market capitalization:
- $2.01B
- Revenue:
- $98.3M
- Net income:
- $-411.3M
- Free cash flow:
- $-377.3M
- Cash:
- $99.6M
- Total debt:
- $31.2M
- EPS:
- -7.01
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.8%.
- Free cash flow is $-377.3M, showing cash burn in the current stored period.
- The balance sheet shows $99.6M of cash versus $31.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.1 points: AGIO increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AGIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.